3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Virus Diseases
1
Tumor Virus Infections
1
Squamous Cell Carcinoma of Head and Neck
1
Pharyngeal Diseases
1
Papillomavirus Infections
1
Otorhinolaryngologic Neoplasms
1
Otorhinolaryngologic Diseases
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Head and Neck Neoplasms
1
DNA Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
pembrolizumab
59
Cisplatin
45
Cetuximab
29
Radiotherapy
26
Carboplatin
24
Docetaxel
17
Paclitaxel
16
Nivolumab
16
Surveys and Questionnaires
15
Radiotherapy, Intensity-Modulated
13
Fluorouracil
12
Drug Therapy
12
Blood Specimen Collection
11
Standard of Care
8
tislelizumab
7
cemiplimab
6
atezolizumab
6
Radiation
6
Chemoradiotherapy
6
toripalimab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
nimotuzumab
4
fludarabine
4
durvalumab
4
dostarlimab
4
Surgical Procedures, Operative
4
Afatinib
4
palbociclib
3
niraparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Nimorazole
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled